In addition to Bcl-2, increased levels of members of the inhibitors of apoptosis (IAP) family including BIRC2, BIRC3, BIRC5/survivin, and XIAP are associated with cisplatin resistance and worse clinical outcome in patients of ovarian, esophageal, or head and neck cancer (Supplementary Table S1). Here, BIRC5 is linked to head and neck cancer.